Metraipolis › archive › dc_764eba5e3035
Cost-effectiveness of degarelix versus LHRH agonists in prostate cancer: a systematic review — Europe PMC PMID:41948305
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41948305
- DOI
- 10.3389/frhs.2026.1608532
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-04T01:50:46.874Z
- SHA-256 of the archived text
2d1caa644775caae1d1351c8a5c04f7dc11492aecdee124b5bc9ba7d5f355ae2- Stable URL of this page
https://metraipolis.com/documento/dc_764eba5e3035
How to cite
Cost-effectiveness of degarelix versus LHRH agonists in prostate cancer: a systematic review — Europe PMC PMID:41948305 — Europe PMC (en), https://europepmc.org/article/MED/41948305 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_764eba5e3035 (Metraipolis archive dc_764eba5e3035, sha256 2d1caa644775caae1d1351c8a5c04f7dc11492aecdee124b5bc9ba7d5f355ae2)
BibTeX
@misc{dc764eba5e3035,
title = {Cost-effectiveness of degarelix versus LHRH agonists in prostate cancer: a systematic review — Europe PMC PMID:41948305},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41948305},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_764eba5e3035; sha256 2d1caa644775caae1d1351c8a5c04f7dc11492aecdee124b5bc9ba7d5f355ae2},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41948305. Agents can read the archived copy with the MCP tool read_document.